Maintenance of the therapeutic efficacy of etanercept in active ankylosing spondylitis patients ahen taper-ing its dosage
10.3969/j.issn.1006-5725.2016.16.013
- VernacularTitle:依那西普逐渐减量对活动性强直性脊柱炎疗效的维持
- Author:
Yujin YE
;
Cuicui WANG
;
Qian QIU
;
Liuqin LIANG
- Publication Type:Journal Article
- Keywords:
Etanecept;
Ankylosing spondylitis;
Dosage tapering;
Therapy
- From:
The Journal of Practical Medicine
2016;32(16):2642-2645
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of etanercept in active ankylosing spondylitis (AS) pa-tient for 48 weeks by tapering the dosage of etanercept every 12 weeks. Methods 52 patients with active AS were enrolled in this study , and 47 patients finished 48 Weeks of observation. 50 mg etanercept was applied subcutaneously once a week for 12 weeks , and was tapered to 50 mg every two weeks for another 12 weeks , and then 25 mg every two weeks for another 24 weeks. BASDAI, BASFI, BASMI, ASDAS, as well as Serum levels of CRP and ESR were doaunented at week 0, 12, 24 and 48, respectively. Result Among the 47 active AS patients, 40 (85.1%) were male, with mean disease duration of 4.1 ± 3.8 years. After 12 -week treatment with 50 mg etanercept weekly, the scores of BASDAI, BASFI, BASMI, ASDAS, as well as levels of ESR and CRP, declined significantly compared to the baseline (P < 0.05, respectively). Despite of tapering the dosage of etan-ercept gradually, most of the patients (87.2%, 41/47) kept in ASAS 40 response during the following 36 weeks. No severe adverse events were observed during the treatment period. Conclusion This study demonstrat-ed the clinical efficacy of etanercept in patients with active AS. A dosage reduction strategy could maintain the clinical efficacy of etanercept during 48 weeks , which indicates that gradually tapering etanercept might be a po-tential effective, economic and safe way for active AS patients.
